Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial

Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial

Abstract Background Recent trials have revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are effective against hyperglycemia and also reduce micro- and macro-vascular complications in patients with type 2 diabetes mellitus (T2DM). Most of the beneficial cardiovascular effects have b...

Full description

Bibliographic Details
Main Authors: Sepehr Gohari, Tara Reshadmanesh, Hadi Khodabandehloo, Mojtaba Fathi, Hassan Ahangar, Shahram Arsang-Jang, Faramarz Ismail-Beigi, Samin Ghanbari, Mohsen Dadashi, Muhammad Javad Muhammadi, Sheida Gohari, Saeid Ghaffari
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cardiovascular Disorders
Subjects:
SGLT2 inhibitor
Empagliflozin
Randomized controlled trial
Coronary artery disease
Inflammation
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1186/s12872-021-02131-1

Internet

https://doi.org/10.1186/s12872-021-02131-1

Similar Items